DGAP-News: curasan AG: Novel bone regeneration material approved for sale in Europe
(firmenpresse) - DGAP-News: curasan AG / Key word(s): Regulatory Approval
curasan AG: Novel bone regeneration material approved for sale in
Europe
28.03.2011 / 14:31
---------------------------------------------------------------------
curasan AG, which is listed in the General Standard of the German Stock
Exchange (ISIN: DE 000 549 453 8), has received European approval for a
novel synthetic bone regeneration material.
Osseolive(R) is a bioactive, poly-crystalline calcium-alkali-phosphate
ceramic, which has a stimulating effect on bone formation as well as on
bone mineralisation.
'With Osseolive(R) emerging from our well-stocked development pipeline, we
now have an ideal extension to our tricalcium-phosphate products', stated
Hans Dieter Rössler, CEO. Osseolive(R) has been specifically designed for
the treatment of large defects in combination with bone growth supporting
substances, such as bone marrow aspirate, stem cells, and bone
morphogenetic proteins (BMPs).'
Background information about curasan AG:
Exchange listed curasan AG (ISIN: DE 000 549 453 8) is one of the leading
companies in the field of regenerative medicine especially in bone and
tissue regeneration. In addition to the synthetic Cerasorb(R) bone
substitution and regeneration material, the company has developed a
future-oriented product pipeline. Some of these various new developments
are ready yet for market rollout. These biomaterials will be marketed
globally by well-positioned contractual partners. Further products will
follow until end of 2012. www.curasan.com
Contact:
curasan AG
Andrea Weidner
Tel. +49 (0)6027 40 900-51
Fax +49 (0)6027 40 900-39
andrea.weidner(at)curasan.de
www.curasan.de
fr financial relations gmbh
Jörn Gleisner
Tel. +49 (0)69 95 90 83 20
Fax +49 (0)69 95 90 83 99
j.gleisner(at)finanical-relations.de
End of Corporate News
---------------------------------------------------------------------
28.03.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: curasan AG
Lindigstraße 4
63801 Kleinostheim
Deutschland
Phone: 06027/40 900 0
Fax: 06027/40 900 29
E-mail: info(at)curasan.de
Internet: www.curasan.de
ISIN: DE0005494538
WKN: 549453
Listed: Regulierter Markt in Frankfurt (General Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
117217 28.03.2011
Datum: 28.03.2011 - 14:31 Uhr
Sprache: Deutsch
News-ID 33604
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 242 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: curasan AG: Novel bone regeneration material approved for sale in Europe"
steht unter der journalistisch-redaktionellen Verantwortung von
curasan AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
